Gremaud S, Fellay B, Hemett OM, Magnin JL, Descombes E. Monthly measurement of high-sensitivity cardiac troponins T and creatine kinase in asymptomatic chronic hemodialysis patients: A one-year prospective study.
Hemodial Int 2021;
26:166-175. [PMID:
34897965 PMCID:
PMC9300151 DOI:
10.1111/hdi.12985]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 08/26/2021] [Accepted: 11/30/2021] [Indexed: 12/12/2022]
Abstract
Background
Cardiology guidelines recommend measuring high‐sensitivity cardiac troponin (hs‐cTn) for the diagnostic work‐up of acute coronary syndromes (ACS). Many hospitals measure hs‐cTnT, but preliminary data have shown that hs‐cTnT is higher than normal in many hemodialysis patients without evidence of ACS. The purpose of this study was therefore to determine the hs‐cTnT levels every month for 1 year in asymptomatic hemodialysis patients, in order to assess their changes over time relative to creatine kinase.
Methods
Fourty‐four hemodialysis patients (mean age 67 ± 14 years) were included. The predialysis levels of fifth‐generation hs‐cTnT, CK, and CK‐MB were measured every month for 1 year using a Cobas® 6000 analyzer (Roche Diagnostics, Switzerland).
Results
Almost 100% of hs‐cTnT measurements were higher than normal (N < 14 ng/L); the mean ± SD annual level was 84 ± 59 ng/L, ranging from a minimum of 24 ± 2 to 241 ± 28 ng/L in individual patients. The mean levels of CK and CK‐MB were normal. Thirteen myocardial infarctions were analyzed, which were all associated with an initial elevation in hs‐cTnT >45% from the individual baseline value. By comparison, CK and CK‐MB only increased in 38% and 31% of these myocardial infarctions, respectively.
Discussion
hs‐cTnT is persistently higher than normal in chronic hemodialysis patients. Standard algorithms for diagnosing ACS can obviously not be used and alternative diagnostic strategies need to be developed. According to our data, and given the huge variation in baseline hs‐cTnT levels among patients, the use of higher cut‐offs as proposed in the literature cannot be recommended. Instead, we consider that hs‐cTnT should be checked at regular intervals (e.g., every 3–6 months) in order to establish individual baseline levels for hs‐cTnT. This approach, in most instances, not only makes it possible to more rapidly rule‐in but also to rapidly rule‐out, cases of ACS in hemodialysis patients who develop cardiac symptoms.
Collapse